Medical network - on March 16, on February 23, a new version of the national health insurance directory in a formal introduction of anxious. In the previous, subject of medical insurance directory to adjust a much-anticipated is domestic innovation medicine and the exclusive product transfer into, these drugs once incorporated into the medical insurance directory, is bound to have a significant impact on the domestic pharmaceutical market pattern change. Directory after, however, people are accidentally found that many had been widely anticipated the innovation of the medicine is absent from the new health insurance directory.
At the same time, another blockbuster information is passed out, 45 high clinical value but relatively expensive, exclusive patent medicines have been determined by expert evaluation, to participate in club of leading a new round of price negotiation by people. In this case, be incorporated into national price negotiation becomes the next these drugs into the medical insurance directory is the only way to eventually, especially the high prices, major disease treatment access will become the key of negotiation.
Recently, from close to the people club department, according to people familiar with the place people club department in the first round of price negotiation directory 45 basic varieties have been confirmed, is now in the confirmation stage, of which about 35 varieties for imported varieties. One of the few domestic varieties are mainly comes from the domestic 1.1 since 2008 approved class of new drugs.
Found, the five varieties most likely to enter negotiations.
1.1 class five new drugs or directory into the talks
Close to the people club department, according to people familiar with the matter with the national health insurance and related policy support to innovative medicines "almost" is different, this year's national price negotiations and the new medical insurance directory adjustment, are fully shows the national level support for innovation in medicine at present.
, according to data from clove garden INSIGHT database since 2008, our country had approved the production of 1.1 class has 13 varieties of new drugs (only chemical medicine, biological medicine not counted), among them, for ek, belong to the first who planning commission dominant price negotiations at the state level, and achieved a 54% drop in the current year. In addition, adefovir ester, ella maud, palmer peramivir sodium chloride, to fluorine milt, iresearch smoothie, cerlords sheen, pioglitazone, and seven varieties also have been included in the 2017 edition of national health insurance directory.
People familiar with the matter, since 2008, our country has approved the 23, including chemical medicines and biological pharmaceutical, 1.1 class new medicine (statistical caliber is different, the actual data may be slightly different), which has clear into the health care have eight, and other types of products such as removing the six vaccine, and nine varieties at present has been officially listed in the national drug prices negotiated. As a result, the rest of the varieties such as hengrui path for, and west of the amine of microchip is likely to be incorporated into the national price negotiations 45 varieties, it is also has been the common expectations.
Products: path for
Company: jiangsu hengrui
Path for Nepal is the world's first in advanced gastric cancer proved effective small molecular targeted drugs, developed independently by jiangsu hengrui medicine, and in October 2014 by CFDA approved and applied to the clinical treatment of advanced gastric cancer, at the same time also is expanding lung cancer, liver cancer, and other indications.
According to relevant data, new cases, 1 million cases of gastric cancer each year, more than 70% in southeast Asia, China ranked first, the south, according to data from 2015 key cities public hospital path for sales of 58.42 million yuan, and can include health definitely had a huge impact on its market volume. For now, many mainstream gastric cancer drugs have been incorporated into health care, for the non-standard products advanced gastric cancer first-line drug for gonow turnover has reached 3 billion yuan, so if the smoothly through further price negotiations into health care, it will usher in a greater market space.
Products: west of the amine
Company: shenzhen microchip
In December 2014, by microchip biological research and development of China's first used in the treatment of non-hodgkin's lymphoma of the original chemical medicine without the approval of the west of the amine by CFDA and officially listed in March 2015. This is the first licensed subtype selectivity of histone acetylation enzyme oral inhibitor, is also China's first authorized patent of the United States and other developed countries the use of original new drugs.
As a new chemical structure of antitumor drugs, west of the amine on price is much lower than similar imported drugs, but also on the curative effect is improved obviously, but because has not yet entered the national health insurance, the cost for the average person is high. West of the amine is after entering medical insurance as well as the national price negotiations for the highest product, for now, the west of the amine hopefully going into the directory.
Products: morpholine indications
Company: jiangsu howson
Morpholine indications by jiangsu howson pharmaceutical research and development with independent intellectual property rights in the first paragraph of the nitro imidazoles anti-infection drugs, launched in 2001, the drug research and development, with 13 years to finally complete, its goods is called Michael spirit, is also great drug discovery of howson pharmaceutical industry to undertake one of the national science and technology major projects. As a new type of the third generation of nitro imidazoles drug, morpholine indications is mainly used for clinical surgical infection caused by anaerobic bacteria and infection of department of gynaecology. In 2016, morpholine indications as innovation medicine in jiangsu province was included in health care.
Products: the anchoring of the effect
Company: anhui universal
Hydrochloride anchoring of the effect of drugs by the Chinese academy of sciences Shanghai scientists first independent research and development with independent intellectual property rights of national first class fluoroquinolone antibacterial drugs, and the Chinese academy of sciences and the national knowledge innovation engineering, implementation of the "major drug discovery" major r&d projects, its as early as April 2009 to win new drug certificate, issued by the CFDA currently have anhui global pharmaceutical production, commodity called best friends.
The effect of products: endure
Company: zhejiang medicine
Zhejiang pharmaceutical production of malic acid nai, the effect of capsule is in October 2016 was successfully listed in national a class of new drugs, zhejiang medicine in June 2012 from too scene biological technology co., LTD., and scene pharmaceutical r&d (Beijing) co., LTD., obtained the product patent rights and rights in China. Data show that the similar products quinolones in 2015 global sales of $2.023 billion.
Price is the same melody
Another information is disclosed, the prices of the early stage of the negotiations were identified 10 varieties, confirmed the 35 species in late stage, and among 35 varieties, almost all of them are imported drugs. This with the current domestic medical market to import the original high drug prices, due to lack of market competition, the international prevailing practice and adopt the way of unification talks, reduce the high prices to a reasonable range. On a number of negotiations, used in the treatment of chronic hepatitis b of tenofovir ester (viread) reduction of 67%.
As for biological drugs approved in recent years, will also be incorporated into an important direction of the negotiations. But due to the current domestic understanding of biological medicine has not yet unified, definition is not clear, therefore temporarily unable to carry on the effective statistics, but there are some more concern of biological medicine, such as compaq heap, and is widely considered will be listed as a new round of price negotiations. In addition, some experts revealed that in 45 countries negotiations among varieties, proprietary Chinese medicine exclusive varieties will not be an exception.
And, more importantly, the negotiations will further embody the basic logic, reduction in "national can pay, patients can pay" as the standard, to ensure that the range of affordable prices down to real patients. From the current payment term, our country's health care orientation is still basic, is a realistic problem from health care to support the development of innovative medicine at present still has the certain difficulty, so make sure that patients use drug accessibility of new mode should be introduced.
In terms of another, support for the innovative drug it's more than enough money problems, research has found that the earliest will be high tumor molecular target drugs into health care, also is not a line's richest province. Compared with well-funded, equally important to form a complete set of rules, standards, implementation and implementation, and hospital level of synergy. In this respect, Shanghai measured by reduction of medicare payments experience might be worth using for reference. |
